Table 3. Univariable and multivariable... | American Society of Hematology

Table 3.

Univariable and multivariable analyses for PFS

	HR	95% CI	P	No. with available data
Univariable analyses
TP53 mutation	2.3	0.81-6.8	.12	45
Del17p	1.3	0.54-3.0	.59	61
Del11q	1.1	0.42-2.7	.91	57
Complex karyotype	1.4	0.53-3.6	.51	42
CLL status at time of alloHCT (partial vs complete remission)	1.7	0.56-5.0	.35	60
HCT-CI				64
≥ 1 vs 0	3.9	1.3-11.5	.015
Continuous, score 0-10	1.2	1.05-1.4	.010
Donor type (matched vs mismatched)	0.88	0.29-2.6	.82	64
Donor (related vs unrelated)	2.7	1.2-6.4	.019	64
CMV Serology (patient pos/donor neg vs all others)	0.66	0.25-1.7	.38	63
Prior ibrutinib	1.4	0.46-4.0	.58	65
Prior venetoclax	1.2	0.54-2.8	.61	65
Prior PI3Ki	0.75	0.25-2.2	.60	65
≥2 prior NAs	1.4	0.63-3.3	.38	65
Chemotherapy refractory	0.76	0.25-2.4	.66	33
Exclusively NAs	0.71	0.26-1.9	.50	63
NA immediately preceding alloHCT (venetoclax vs ibrutinib)	0.96	0.39-2.4	.92	56
Multivariable analyses
HCT-CI (≥1 vs 0)	3.3	1.1-9.9	.035	64
Donor (related vs unrelated)	2.2	0.94-5.2	.07	64

	HR	95% CI	P	No. with available data
Univariable analyses
TP53 mutation	2.3	0.81-6.8	.12	45
Del17p	1.3	0.54-3.0	.59	61
Del11q	1.1	0.42-2.7	.91	57
Complex karyotype	1.4	0.53-3.6	.51	42
CLL status at time of alloHCT (partial vs complete remission)	1.7	0.56-5.0	.35	60
HCT-CI				64
≥ 1 vs 0	3.9	1.3-11.5	.015
Continuous, score 0-10	1.2	1.05-1.4	.010
Donor type (matched vs mismatched)	0.88	0.29-2.6	.82	64
Donor (related vs unrelated)	2.7	1.2-6.4	.019	64
CMV Serology (patient pos/donor neg vs all others)	0.66	0.25-1.7	.38	63
Prior ibrutinib	1.4	0.46-4.0	.58	65
Prior venetoclax	1.2	0.54-2.8	.61	65
Prior PI3Ki	0.75	0.25-2.2	.60	65
≥2 prior NAs	1.4	0.63-3.3	.38	65
Chemotherapy refractory	0.76	0.25-2.4	.66	33
Exclusively NAs	0.71	0.26-1.9	.50	63
NA immediately preceding alloHCT (venetoclax vs ibrutinib)	0.96	0.39-2.4	.92	56
Multivariable analyses
HCT-CI (≥1 vs 0)	3.3	1.1-9.9	.035	64
Donor (related vs unrelated)	2.2	0.94-5.2	.07	64